Pharmacognosy Magazine

ORIGINAL ARTICLE
Year
: 2022  |  Volume : 18  |  Issue : 78  |  Page : 304--313

Efficacy of bisacurone in bone fracture healing process: An experimental study on osteoporotic rats


Minjie Li1, Weiwei Feng2, Wenping Zhang3, Zhonghui Pang1, Shaokun Pei1, Lifeng Xia1, Qiang Li1, Huixiao Li1 
1 Department of Orthopedics, The Fourth People's Hospital of Shaanxi, Xi'an, China
2 Department of Maxillofacial Oncology, The Third Affiliated Hospital of Air Force Military Medical University, Xi'an, China
3 Department of Blood Transfusion, The First Affiliated Hospital of Air Force Military Medical University, Xi'an, China

Correspondence Address:
Huixiao Li
Department of Orthopedics, The Fourth People's Hospital of Shaanxi, Xi'an - 710043
China

Background: Osteoporosis (OP) is a common disorder resulting in bone fragility and fracture. Due to OP, bone mass and microarchitectural bone tissues are damaged, increasing the risk of fracture. Objectives: To determine the efficacy of bisacurone in healing fractured bones and its inflammatory response in ovariectomy (OVX)-induced OP in female rats. Materials and Methods: After inducing fracture in femur bone, bisacurone (25, 50, and 100 μg/kg) and alendronate (20 mg/kg) were orally administered to rats for 8 weeks. Subsequently, its fracture healing and anti-inflammatory potential were evaluated via assessment of various biochemical and molecular parameters. Results: Bisacurone therapy significantly (P < 0.05) increased the calcium content, serum calcium, and phosphorus in OVX-induced OP rats. It significantly (P < 0.05) reduced the serum alkaline phosphate (ALP); urine biochemical parameters such as urinary calcium, phosphorus, and creatinine; and inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor α (TNF-α). Moreover, bisacurone was found to be significantly (P < 0.05) effective in downregulating the bone turnover markers such as osteocalcin, receptor activator of nuclear factor-kappa-γ ligand (RANKL), peroxisome proliferator-activated receptor gamma (PPAR-γ), and upregulating osteoprotegerin (OPG), runt-related transcription factor 2 (Runx2), and AMP-activated protein kinase (AMPK) in OVX-induced OP rats. Conclusion: Bisacurone effectively healed the fracture and improved the bone quality in arthritic conditions by reducing inflammatory cytokines and altering the level of bone turnover markers. Therefore, bisacurone therapy should be considered for the management of fracture healing process in the arthritic conditions.


How to cite this article:
Li M, Feng W, Zhang W, Pang Z, Pei S, Xia L, Li Q, Li H. Efficacy of bisacurone in bone fracture healing process: An experimental study on osteoporotic rats.Phcog Mag 2022;18:304-313


How to cite this URL:
Li M, Feng W, Zhang W, Pang Z, Pei S, Xia L, Li Q, Li H. Efficacy of bisacurone in bone fracture healing process: An experimental study on osteoporotic rats. Phcog Mag [serial online] 2022 [cited 2022 Sep 27 ];18:304-313
Available from: http://www.phcog.com/article.asp?issn=0973-1296;year=2022;volume=18;issue=78;spage=304;epage=313;aulast=Li;type=0